Capricor Therapeutics (NASDAQ:CAPR) Share Price Passes Above Fifty Day Moving Average – Here’s Why

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s share price passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $26.80 and traded as high as $29.27. Capricor Therapeutics shares last traded at $27.77, with a volume of 745,376 shares.

Analyst Ratings Changes

CAPR has been the subject of several analyst reports. Oppenheimer increased their price target on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Wall Street Zen downgraded shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Capricor Therapeutics in a research note on Monday, December 29th. B. Riley Financial increased their target price on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Finally, Alliance Global Partners restated a “buy” rating on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.09.

Capricor Therapeutics Stock Down 3.9%

The firm has a market cap of $1.60 billion, a PE ratio of -12.29 and a beta of 0.37. The stock has a 50 day moving average price of $26.80 and a two-hundred day moving average price of $18.49.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11). As a group, equities analysts anticipate that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in shares of Capricor Therapeutics by 16.1% during the fourth quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock valued at $73,936,000 after buying an additional 355,161 shares during the last quarter. Suvretta Capital Management LLC purchased a new position in Capricor Therapeutics in the 4th quarter worth $51,533,000. Tang Capital Management LLC purchased a new position in Capricor Therapeutics in the 4th quarter worth $49,062,000. RA Capital Management L.P. acquired a new stake in Capricor Therapeutics during the 4th quarter worth about $43,516,000. Finally, Geode Capital Management LLC lifted its position in Capricor Therapeutics by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 1,017,332 shares of the biotechnology company’s stock worth $29,367,000 after acquiring an additional 55,766 shares during the period. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.